The use of Botulinum Toxin Type A in patients in out-of-hospital intensive care in Germany-results from a multidisciplinary online survey.
Abstract
[INTRODUCTION] In Germany, approximately 23.000 patients live in of out-of-hospital intensive care settings. About 80% suffer from neurological diseases and are prone to spasticity and sialorrhea, both of which can be effectively treated with Botulinum Toxin Type A (BoNT-A). This study investigates the utilization, barriers, and training needs associated with BoNT-A application.
[METHODS] An online questionnaire with 10 questions was developed by the German Interdisciplinary Society for Out-of-Hospital Ventilation and Intensive Care (DIGAB). The survey was distributed via the mailing lists of the DIGAB, the German Society for Respiratory Therapy, and the nursing supervisors of the Deutsche Fachpflege nursing service, as well as to speech and language therapists through a private mailing list.
[RESULTS] The survey was sent to 702 recipients, with 41 healthcare professionals completing the survey. Only 160 (20%) of 789 patients with spasticity and 111 (14%) of 816 patients with sialorrhea or salivary aspiration received BoNT-A treatment. Barriers included the lack of trained providers, logistical challenges, and uncertainty regarding cost coverage. Participants emphasized the importance of staff training, availability of medical specialists and treatment in the home environment.
[CONCLUSION] Despite its potential to facilitate care, to improve quality of life, and to promote participation in out-of-hospital intensive care, BoNT-A remains underused. Key requirements include education on multidisciplinary treatment of spasticity and sialorrhea, adequate reimbursement for BoNT-A administration, a coordinating role for the neurologist in the regulatory framework of out-of-hospital intensive care, and integration of BoNT-A in treatment guidelines are required. Further research should collect patient-level data on spasticity, dystonia, sialorrhea, and BoNT-A treatment, and examine healthcare delivery across different healthcare structures.
[METHODS] An online questionnaire with 10 questions was developed by the German Interdisciplinary Society for Out-of-Hospital Ventilation and Intensive Care (DIGAB). The survey was distributed via the mailing lists of the DIGAB, the German Society for Respiratory Therapy, and the nursing supervisors of the Deutsche Fachpflege nursing service, as well as to speech and language therapists through a private mailing list.
[RESULTS] The survey was sent to 702 recipients, with 41 healthcare professionals completing the survey. Only 160 (20%) of 789 patients with spasticity and 111 (14%) of 816 patients with sialorrhea or salivary aspiration received BoNT-A treatment. Barriers included the lack of trained providers, logistical challenges, and uncertainty regarding cost coverage. Participants emphasized the importance of staff training, availability of medical specialists and treatment in the home environment.
[CONCLUSION] Despite its potential to facilitate care, to improve quality of life, and to promote participation in out-of-hospital intensive care, BoNT-A remains underused. Key requirements include education on multidisciplinary treatment of spasticity and sialorrhea, adequate reimbursement for BoNT-A administration, a coordinating role for the neurologist in the regulatory framework of out-of-hospital intensive care, and integration of BoNT-A in treatment guidelines are required. Further research should collect patient-level data on spasticity, dystonia, sialorrhea, and BoNT-A treatment, and examine healthcare delivery across different healthcare structures.
추출된 의학 개체 (NER)
| 유형 | 영어 표현 | 한국어 / 풀이 | UMLS CUI | 출처 | 등장 |
|---|---|---|---|---|---|
| 시술 | botulinum toxin
|
보툴리눔독소 주사 | dict | 2 | |
| 해부 | salivary
|
scispacy | 1 | ||
| 약물 | [INTRODUCTION] In
|
scispacy | 1 | ||
| 약물 | BoNT-A
→ Botulinum Toxin Type A
|
scispacy | 1 | ||
| 질환 | neurological diseases
|
C0027765
nervous system disorder
|
scispacy | 1 | |
| 질환 | spasticity
|
C0026838
Muscle Spasticity
|
scispacy | 1 | |
| 질환 | sialorrhea
|
C0037036
Sialorrhea
|
scispacy | 1 | |
| 질환 | dystonia
|
C0013421
Dystonia
|
scispacy | 1 | |
| 기타 | Botulinum Toxin Type A
|
scispacy | 1 | ||
| 기타 | patients
|
scispacy | 1 | ||
| 기타 | BoNT-A
→ Botulinum Toxin Type A
|
scispacy | 1 |
🔗 함께 등장하는 도메인
이 논문이 속한 카테고리와 같은 논문에서 자주 함께 다뤄지는 카테고리들
관련 논문
- Local therapeutic strategies for neurocutaneous dysesthesia: from capsaicin to cannabinoids.
- Comparative efficacy of intralesional therapies for keloid scars: a network meta-analysis.
- Adverse neurological events following botulinum toxin type A: A case series of post-injection seizures and paralysis.
- Decreased utilization of component separation techniques over time in complex abdominal wall reconstruction following introduction of preoperative botulinum toxin A.
- Current Perspectives on Pectoralis Minor Syndrome: A Narrative Review.